Adcentrx Therapeutics

Antibody drug conjugate 

ADRX-0405 Clin0 oncology; ADRX134 RD oncology; undisclosed programs RD oncology

Adcentrx Therapeutics is using protein conjugate technology to create therapies for cancer and other diseases. Antibody-drug conjugates (ADCs) are a therapeutic approach that deliver toxic payloads into a diseased cell. However, ADCs come with limitations such as fast clearance leading to lower efficacy and premature release of payloads causing off-target toxicity. Adcentrx is using their “Toolbox” to pioneer stable conjugation chemistry they refer to as the i-ConjugationTM technology. Using this technology, Adcentrx is improving payload delivery to the target, allowing higher dosing and better tumor penetration. In addition, Adecntrx is optimizing the targeting moiety, linker and payload to reduce manufacturing complexity and to tackle heterogeneous tumors.